$70M immunotherapy startup launches with backing from Pfizer, Astellas


The venture arms of life sciences giants and a biotech real estate developer are backing a brand-new startup launched by the Longwood Fund.

Previous First Bank extends growth streak with $181M deal for SC's GrandSouth Bank
Next 2022 Diversity in Business Awards: How 26Health strives to create equity in the Orlando area's patient populations